China Biosimilars Market Size & Share 2026-2035

China Biosimilars Market Size

China's biosimilars market is valued at USD 4.6 billion in 2025 and is projected to reach USD 23.6 billion by 2035, representing a 17.5% CAGR, according to GMI to the latest report published by Global Market Insights Inc.

The supply base has moved beyond early recombinant proteins toward a broader antibody and complex-biologic pipeline. China approved 57 biosimilars across seven therapeutic categories from January 2019 through April 2025, with a median application-to-approval interval of 1.40 years. ^{[3]Chinese Journal of Pharmacy, Characteristics and Indication Comparison of Approved Biosimilars in China. chinjmap.com} That expansion is commercially meaningful only when it is translated into funded hospital use. The 2023 National Reimbursement Drug List added 126 drugs, and negotiated or competitively included products saw an average 61.7% price reduction. ^{[4]China National Healthcare Security Administration, 2023 NRDL Announcement. nhsa.gov.cn}

China's regulatory design increases the importance of process control. The 2015 biosimilar guideline established technical-review principles, biosimilarity criteria, and a pathway for indication extrapolation. ^{[5]Ropes & Gray Insights, China Announces Final Biosimilars Guideline. ropesgray.com} Product development is assessed through pharmaceutical, non-clinical, pharmacokinetic, and clinical comparability, as illustrated by the NMPA review of Hengrui's BP-102 bevacizumab biosimilar. ^{[6]NMPA Technical Review Report, Bevacizumab Injection (BP-102). file1.dxycdn.com} For developers, this makes analytical capability and manufacturing consistency strategic assets rather than back-office functions.

China's approval pathway has lowered uncertainty relative to the market's formative years, but it has also shifted the competitive test toward CMC discipline, indication strategy, and launch readiness. Developers that can convert approval into hospital access without overextending on tender price should be better positioned than companies relying on a single late-stage asset.

Key Drivers

China's disease burden creates a durable clinical base for oncology, metabolic, autoimmune, and hematology-related biosimilars. Cancer alone generated approximately 2.57 million deaths in 2022. ^{[1]Cancer Communications, Cancer situation in China: an analysis based on global epidemiological data released in 2024. journal.hep.com.cn} The estimated diabetes prevalence was 15.88% in 2023, supporting demand for insulin and incretin-related therapies. ^{[2]Military Medical Research, National and provincial prevalence of diabetes in China 2005-2023. link.springer.com} The expiration of semaglutide's Chinese patent in 2026 has intensified interest in a new class of metabolic follow-ons. ^{[7]Reuters, Novo Nordisk braces for generic challenge to Ozempic, Wegovy in China. reuters.com} The commercial opportunity is therefore moving from molecules with long-established physician familiarity to higher-value biologics whose access can be constrained by originator cost.

Centralized procurement is the mechanism that turns a lower list price into volume. From 2018 to 2022, seven national volume-based procurement rounds cut prices by an average of 53% across 294 formulations; winning suppliers received procurement commitments equivalent to 60%-70% of prior-year consumption. ^{[8]BMJ Global Health, Improving access to medicines: the national volume-based procurement policy in China. gh.bmj.com} Biosimilar procurement has progressed from Wuhan's 2020 insulin pilot toward alliance procurement for monoclonal antibodies. ^{[9]NRDLPlus, China's Biosimilar VBP: Emerging Rules, Pricing Dynamics, and What Early Signals Suggest. nrdlplus.com} This structure favors suppliers that can protect batch reliability and distribution performance after making an aggressive bid.

Manufacturing capability is broadening alongside demand for antibodies. Chinese producers have increasingly adopted mammalian expression systems as therapeutic monoclonal-antibody pipelines expanded. ^{[10]BioProcess International, Demand for Capacity Drives China's Biomanufacturing Expansion. bioprocessintl.com} WuXi Biologics reports more than 260,000 L of drug-substance capacity across CHO, NS0, and HEK platforms, with planned capacity above 580,000 L. Such infrastructure can shorten the distance between development and commercial supply, but it also raises the cost of unused capacity when tender-driven prices compress.

Key Restraints

Clinical adoption is a separate constraint from regulatory approval. In a nationwide 2022 survey, only 57.58% of physicians had prescribed a biosimilar, fewer than one-third of patients had used one, and only 15.78% of healthcare professionals correctly understood interchangeability regulation. Concerns about immunogenicity, safety, and post-switch efficacy were reported by 62.87%, 60.68%, and 52.91% of surveyed physicians, respectively. China had no clear interchangeable-biosimilar definition in its review and registration process at that time, which limits the ability of procurement policy alone to normalize switching.

Price pressure can also undermine the commercial logic of participation. Volume-based procurement guarantees utilization only for winners, so a lower-priced tender can improve access while narrowing the cash available for pharmacovigilance, commercial education, and capacity maintenance. This creates a practical barrier for smaller sponsors and CDMOs that lack a multi-product base over which to spread quality-system costs.

The key friction is not a lack of biosimilar demand; it is the conversion of formal comparability into confidence at the point of prescribing. Patent linkage adds a legal timing risk, while uncertainty over interchangeability and switching slows uptake among stable originator users. Commercial models that combine tender readiness with medical education and post-market evidence should be more resilient than models built exclusively around a low initial bid.

China Biosimilars Market Segment Analysis

Product

Recombinant glycosylated proteins account for 65.29% of the market in 2025, or USD 2,987.65 million, and are projected to exceed USD 15.3 billion by 2035, according to GMI proprietary analysis. Their 17.45% CAGR reflects the scale of monoclonal antibodies - particularly infliximab, rituximab, adalimumab, trastuzumab, and bevacizumab - as well as erythropoietin, follitropin alfa/beta, and fusion proteins. Antibodies already represent more than half of approved Chinese biosimilars. The segment's economic significance arises from the combination of high originator spend and hospital-led treatment pathways, although its manufacturing burden is greater because glycosylation and other critical quality attributes must be controlled across mammalian-cell production.

Recombinant non-glycosylated proteins represent 28.88% of 2025 revenue, or USD 1,321.23 million, with a 17.75% CAGR in GMI proprietary analysis. This category includes human growth hormone, filgrastim, insulin, and interferon alfa and beta. It retains strategic relevance because procurement experience and treatment familiarity can support scale, while diabetes alone creates a very large addressable population. Other products account for the remaining 5.83%, or USD 266.77 million. The advance of dulaglutide biosimilars shows that the boundary between established proteins and technically demanding next-generation products is becoming less distinct: Boan reported overcoming oxidation and charge-heterogeneity challenges for BA5101.

Application

Hematology is the largest application at 31.80% of 2025 revenue, or USD 1,454.88 million, and is expected to reach USD 7.3 billion during the forecast period, according to GMI proprietary analysis. Neutropenia, anemia, and other hematology uses benefit from treatment protocols that connect supportive care with chemotherapy and chronic kidney disease. China had an estimated 156.15 million people with chronic kidney disease in 2023, supporting continuing demand for anemia-related biologics.

Autoimmune disease contributes 24.51% of 2025 revenue, or USD 1,121.28 million, led by arthritis - including rheumatoid, psoriatic, juvenile, and ankylosing forms - IBD, psoriasis, and other autoimmune diseases. China had 4.76 million prevalent rheumatoid-arthritis cases in 2021. This segment offers volume potential for anti-TNF and other biosimilars, but switching concerns make physician confidence especially consequential. Oncology accounts for 20.63%, or USD 943.90 million, and has the highest application CAGR at 18.13%, according to GMI proprietary analysis. Lung, brain, breast, cervical, colorectal, leukemia, and other oncology indications increasingly draw on antibody biosimilars, with hospital protocol inclusion likely to matter as much as the molecule's approval status.

Diabetes represents 12.54% of 2025 revenue, or USD 573.85 million; growth hormone deficiency represents 5.74%, or USD 262.63 million; ophthalmology represents 2.85%, or USD 130.43 million; and other applications comprise 1.94%, or USD 88.68 million, according to GMI proprietary analysis. Diabetes is the most exposed to a potential step-change in competitive intensity as GLP-1 follow-ons emerge, whereas ophthalmology remains smaller but depends on specialist prescribing and tightly controlled product handling.

Manufacturing Type, Technology, and Distribution

In-house manufacturing accounts for 61.15% of 2025 revenue, or USD 2,797.90 million, compared with 38.85% for contract research and manufacturing services, according to GMI proprietary analysis. Vertical integration supports control over comparability, supply, and tender fulfillment; contract services, growing at 17.75%, offer a route for asset-light developers but require strong technology transfer and quality oversight. Recombinant DNA technology remains the core enabling platform. Mammalian cell culture systems are central to complex antibodies and glycosylated proteins, while other technologies address molecule-specific requirements.

Hospital pharmacies hold 56.1% of 2025 distribution-channel revenue in GMI proprietary analysis. This reflects China's institution-centered biologic prescribing and the linkage between centralized procurement, formulary decisions, and infusion or specialty administration. Specialty pharmacies can expand for therapies requiring cold-chain management, refill support, or patient education, but their role is constrained when hospital tender decisions determine initial access.

The most attractive application segments are not necessarily those with the fastest reported growth. Oncology combines strong growth with institutional adoption and an expanding antibody base, whereas autoimmune care requires a more deliberate switching strategy. Diabetes may become a major competitive inflection point as GLP-1-related patent expiries and complex fusion-protein manufacturing bring new entrants into a market where scale is substantial but legal and CMC risks remain material.

China Biosimilars Market Regional Analysis

China is a single national market, but biosimilar adoption is not geographically uniform. A hospital-procurement analysis across 2,253 hospitals in 30 provinces found that trastuzumab biosimilar penetration reached 27% in February 2023; provinces with faster uptake generally had higher basic health-insurance coverage, lower urbanization, and lower GDP per capita. The finding challenges a simple assumption that wealthier provinces adopt first. Where patient affordability pressure is stronger and basic insurance reaches more residents, the relative value of a lower-cost biosimilar can be more visible.

Tertiary hospitals function as important adoption nodes because familiarity with biologic treatment and evidence review is concentrated there. Research on anti-tumor biosimilars notes faster uptake in tertiary hospitals and different physician comfort levels by drug class, including stronger comfort with anti-angiogenic agents than with targeted therapies. Their protocol committees can accelerate acceptance, but they can also make local education and pharmacovigilance evidence prerequisites for switching.

Provincial implementation matters because reimbursement architecture, hospital purchasing practices, and local clinical networks determine whether a national policy reaches an individual patient. The 2024 Chinese evidence-based guideline issued 10 recommendations covering physician, pharmacist, and patient management. Its operational value lies in reducing variation in how hospitals communicate comparability, manage switches, and document safety, particularly outside the largest metropolitan centers.

Tertiary hospitals remain essential for legitimizing use in complex oncology and autoimmune indications, but they are also where evidence thresholds can be highest. A successful geographic strategy pairs provincial procurement intelligence with hospital-specific medical education, then uses experienced centers to support diffusion into regional institutions. That approach is more defensible than a uniform sales deployment across provinces.

China Biosimilars Market Share & Competitive Landscape

The market is moderately concentrated. Shanghai Henlius Biotech, Bio-Thera Solutions, Innovent Biologics, 3SBio, and Qilu Pharmaceutical collectively hold approximately 58% of 2025 market revenue, according to GMI proprietary analysis. Competition centers on molecule breadth, tender economics, manufacturing reliability, and the ability to translate approval into hospital use rather than on discovery differentiation alone.

Shanghai Henlius has built a portfolio spanning rituximab, trastuzumab, adalimumab, bevacizumab, and pertuzumab biosimilars; the NMPA approved its HLX11 pertuzumab biosimilar in May 2026. Bio-Thera combines China activity with international biosimilar execution; its tocilizumab biosimilar BAT1806 received NMPA approval in January 2023. Innovent has marketed rituximab, bevacizumab, and adalimumab biosimilars alongside its innovative portfolio. 3SBio's etanercept and trastuzumab franchises illustrate how established recombinant-protein and oncology assets can coexist: Cipterbin sales increased 48.9% year over year in the first half of 2024. Qilu's approvals in denosumab and pertuzumab demonstrate continued movement into more complex oncology-supportive and HER2-directed products.

The remaining authorized companies occupy differentiated positions. Gan & Lee Pharmaceuticals and Tonghua Dongbao Pharmaceutical provide insulin and metabolic-biologics exposure; Tonghua Dongbao received NMPA approval for its liraglutide biosimilar in 2023. Hengrui Medicine, Hisun Pharmaceutical, Junshi Biosciences, and Mabwell Bioscience contribute biosimilar portfolios or commercialization assets, including Mabwell's denosumab biosimilar. BeiGene's connection is limited to commercializing Bio-Thera's bevacizumab biosimilar in China; it should not be viewed as a biosimilar developer. Akeso and RemeGen are innovative-biologics companies with no approved biosimilars, relevant to competitive dynamics in oncology and other biologic treatment areas rather than direct biosimilar rivalry.

This structure means that portfolio comparisons require care. A company's innovative-drug revenue, ADC program, or bispecific-antibody platform does not automatically confer biosimilar manufacturing or tender capability. Conversely, domestic biosimilar specialists can use international approvals and manufacturing scale to diversify demand beyond Chinese procurement cycles.

Recent Industry Developments

On May 29, 2026, NMPA approved Shanghai Henlius Biotech's pertuzumab biosimilar HANBEIYOU (HLX11) for Perjeta-referenced indications in China.

On August 8, 2025, NMPA approved Boan Biotech's Boyouping (BA5101) for glycemic control in adults with type 2 diabetes; the company described it as the first and only marketed dulaglutide biosimilar worldwide.

On December 1, 2025, Fresenius Kabi launched the denosumab biosimilars Conexxence and Bomyntra in Europe after European Commission authorization in July 2025.

On November 21, 2023, Sandoz launched the citrate-free, high-concentration Hyrimoz adalimumab formulation in Europe, with progressive availability across markets.